Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK2231395A · 1 trial · 2 indications
Solicited local symptoms assessed were pain, redness and swelling. Any solicited local symptom was defined as occurrence of any solicited local symptom regardless of intensity grade. Solicited general symptoms assessed were fatigue, gastrointestinal, headache, malaise, myalgia and temperature Any temperature was defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C). For other symptoms: Any = any general symptom reported irrespective of intensity grade and relationship to vaccination.
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study. Also any "solicited" symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination.
Biochemical parameters assessed in blood samples include alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA) and urea (URE). Abnormalities reported include values outside the normal ranges. Time points were presented as before (Pre) or after (Post) Dose 1, 2 or 3.
Hematological parameters assessed in blood samples include red blood cells (RBC), white blood cells (WBC - including Basophils (BAS), neutrophils (NEU), lymphocytes (LYM), eosinophils (EOS) and monocytes (MON), blood platelets (PLA) and Hemoglobin (HEM). Abnormalities reported include values outside the normal ranges. This outcome presents results for RBC, WBC High and Low, PLA and HEM. Time points were presented as before (pre) or after (post) doses 1, 2 or 3.
| Arm | Type | Description |
|---|---|---|
| GSK2254233A Group | EXPERIMENTAL | Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm. |
| GSK2254232A Group | EXPERIMENTAL | Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm. |
| Engerix Group | ACTIVE_COMPARATOR | Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm. |
| Name | Type | Description |
|---|---|---|
| GSK2231395A | BIOLOGICAL | Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2. Two different formulations of this vaccine will be tested. |
| Engerix-B | BIOLOGICAL | Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2. |
Inclusion Criteria: * Subjects who the investigator believes will comply with the requirements of the protocol should be enrolled in the study. * A male or female between, and including, 18 and 40 years of age at the time of the first vaccination. * Written informed consent obtained from the subjec...
GSK2231395A is an investigational monoclonal antibody being developed for Streptococcus pneumoniae, a bacterial cause of pneumonia and other infections. It is in Phase 1 clinical development for this infectious disease indication. The drug is not approved and remains under study.
GSK2231395A is being developed by GSK plc, a global biopharmaceutical company traded on the London Stock Exchange under the ticker GSK. The company is conducting clinical research on this investigational monoclonal antibody for Streptococcus pneumoniae.
GSK2231395A is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains under clinical investigation for Streptococcus pneumoniae.
GSK2231395A has one completed Phase 1 trial, NCT00814489, titled "Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults." The study enrolled 40 healthy volunteers in Sweden and was randomized, double-blind, and active-controlled.
GSK2231395A is a monoclonal antibody, not a vaccine. The completed clinical trial NCT00814489 evaluated vaccine formulations for Streptococcus pneumoniae and Haemophilus influenzae, but the drug itself is an antibody being studied for potential use against Streptococcus pneumoniae.